ng28ÄϹ¬

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (A¦Â) protofibril antibody, for the treatment of early Alzheimer¡¯s disease with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).

TOKYO and CAMBRIDGE, Mass., May 16, 2023 ¨C Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI?), an investigational anti-amyloid beta (A¦Â) protofibril* antibody, for the treatment of early Alzheimer¡¯s disease (mild cognitive impairment due to Alzheimer¡¯s disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain.

Feng Yanhui, President of Eisai China, visited SINOPHARM Holding Henan Co., Ltd for business research, accompanied by Li Yunlong, VP of Eisai China, Zhao Jianjun, Director of North China Access Department, and Xia Ruiying, Manger of North China Access Department in Eisai China. Chen Zhanyu, Vice President of SINOPHARM Holding and Chairman of SINOPHARM Holding Henan, Zhang Zhaohui, General Manager of SINOPHARM Holding Henan, Xu Hai, Deputy General Manager of SINOPHARM Holding Global Procurement and Supply Chain Service Center , Li Jie, Assistant General Manager of SINOPHARM Holding Henan, and Yang Fan, Director of Supply Chain Business Development Department of SINOPHARM Holding received Feng Yanhui and her delegation.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (Headquarters: Zhejiang Province, China, ¡°BlissBio¡±), for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.

The “National Kickoff Meeting of Lecturer Group on Gastrointestinal Mucosa ” was grandly held on April 14th at the Inner Mongolia Building in Beijing, accompanied by the 2023 Beijing Union Medical College International Digestive Disease Forum.

AS A GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women¡¯s Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.

Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai¡¯s Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer¡¯s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that it was selected as the winner of the ¡°Basic Achievement Grand Prize¡± at the ¡°2023 J-Win Diversity Award¡± held by non-profit organization Japan Women’s Innovative Network (NPO J-Win).

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ¡°Eisai¡±) announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan¡¯s Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.